Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) - Investment analysts at HC Wainwright lifted their Q3 2025 earnings estimates for shares of Armata Pharmaceuticals in a research note issued on Wednesday, August 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.42) per share for the quarter, up from their previous estimate of ($0.50). HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Armata Pharmaceuticals' current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Armata Pharmaceuticals' Q4 2025 earnings at ($0.41) EPS and FY2025 earnings at ($1.46) EPS.
Armata Pharmaceuticals Stock Up 2.4%
Armata Pharmaceuticals stock traded up $0.06 during mid-day trading on Friday, reaching $2.61. 9,202 shares of the company traded hands, compared to its average volume of 9,261. Armata Pharmaceuticals has a fifty-two week low of $0.90 and a fifty-two week high of $2.96. The firm has a market capitalization of $94.56 million, a P/E ratio of -2.53 and a beta of 0.99. The company has a fifty day moving average price of $2.24.
Hedge Funds Weigh In On Armata Pharmaceuticals
A hedge fund recently bought a new stake in Armata Pharmaceuticals stock. GSB Wealth Management LLC purchased a new stake in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 30,000 shares of the company's stock, valued at approximately $57,000. GSB Wealth Management LLC owned 0.08% of Armata Pharmaceuticals as of its most recent filing with the SEC. 3.57% of the stock is owned by hedge funds and other institutional investors.
About Armata Pharmaceuticals
(
Get Free Report)
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Featured Articles
Before you consider Armata Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Armata Pharmaceuticals wasn't on the list.
While Armata Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access